30 closest matches · ranked by relevance
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
HLRCC · Sporadic Papillary Renal Cell Cancer
Primary: Overall Response Rate — 72; 35 Percentage of participants
Gingival Bleeding · Von Willebrand Diseases
Primary: Bleeding on Probing (BOP) — 14.5; 12.3 percentage of sites
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Type 3 Von Willebrand's Disease
Primary: Centralized Factor VIII (FVIII) Procoagulant Activity (FVIII:C) Laboratory Test for Type 3 Von Willebrand's Disease (VWD3) Diagnosis — 2.42 IU/dL
Diabetic Kidney Disease (DKD)
Primary: Percent Change From Baseline in Urinary Albumin-to-creatinine Ratio (ACR) — 3.2; 17.7; 5.4 Geometric Mean of Percent Change — p=0.485
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
Malignant Melanoma
Primary: T 1/2 — 9.94 hr
Polycystic Ovary Syndrome · Vitamin D Deficiency
Primary: Effect of Vitamin D on Angiogenic Factors — 6.7; 5.6; 5.9; 5.5 ratio
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Neurofibromatosis Type 2 · Progressive Vestibular Schwannomas
Primary: Improvement in Hearing — 9 Participants
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
Age Related Macular Degeneration · Choroidal Neovascularization · Macular Edema
Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Paraganglioma · Pheochromocytoma
Primary: Clinical Benefit Rate (CBR) Which is Defined as Either a Partial Response (PR) Complete Response (CR) or Stable Disease (SD) for ≥ 12 Weeks Measured Using Response…
End-stage Renal Disease
Primary: Arteriovenous Fistulae Maturation — 50; 40 percentage of group
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Secondary Hyperparathyroidism
Primary: The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours — 40.6; 46.2; 39.8; 58.8 pg/ml — p=0.1
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)